Skip to main content

Table 3 Modulation of costimulatory and coregulatory molecule expression by iv-SIL

From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

MFI (mean ± SD) pDC   mDC  
  Pre Post p Pre Post p
HLA-DR 1673.5 ± 525.4 1523.4 ± 531.1 0.0092 2867.8 ± 440.9 2661.0 ± 573.2 0.1507
CD83 548.5 ± 187.7 755.0 ± 683.6 0.3982 374.9 ± 108.1 620.7 ± 392.5 0.0865
CD86 714.7 ± 174.0 743.6 ± 139.0 0.6359 1462.2 ± 322.8 1303.2 ± 328.0 0.4298
ICOSL 554.1 ± 223.8 640.4 ± 209.8 0.5265 498.2 ± 257.8 501.2 ± 133.7 0.9219
PD-L1 316.1 ± 110.7 376.8 ± 111.7 0.1848 272.0 ± 68.9 326.1 ± 88.6 0.1311
HLA-G 356.7 ± 57.8 409.9 ± 62.3 0.0583 567.7 ± 120.5 587.5 ± 108.4 0.6944
IL-T4 2303.6 ± 632.8 2743.4 ± 718.6 0.0165 1797.7 ± 424.0 2294.4 ± 570.7 0.0669
CD39 349.7 ± 116.9 437.8 ± 143.6 0.0456 1516.8 ± 269.2 1761.7 ± 527.6 0.2601
PD-L1/CD86 0.447 ± 0.110 0.5217 ± 0.197 0.3830 0.189 ± 0.042 0.268 ± 0.116 0.0929
  1. PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86, ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (MFI, mean SD) as well as the PD-L1/CD86 ratio on mDC and pDC is reported. Italicized values denote significance